Israel-based AI biotech company Biolojic Design has collaborated with Merck KGaA to design therapeutic antibodies to treat cancer and immunological disorders. As part of the agreement, Biolojic Design will receive a low double-digit million Euro upfront payment, milestone payments amounting to EUR 346 million (USD 376 million), and royalties on sales.

The partnership will leverage Biolojic’s AI capabilities to create potential antibody-based therapies, including antibody-drug conjugates (ADCs) useful for cancer treatment. 

Biolojic Design specializes in the computational design of functional antibodies. Leveraging AI, it transforms antibodies into intelligent medicinal solutions targeting specific epitopes to perform novel biological functions. The company's platform produces mono-specific and multi-specific antibodies to treat autoimmune diseases and cancers by precisely modulating biological pathways.